PD 146176, >=98% (HPLC), solid

PD 146176, >=98% (HPLC), solid

Application

PD 146176 has been used to study its influence on ex vivo leukotriene B4 (LTB4) and lipoxin A4 (LXA4) secretion in adipose tissue.

Biochem/physiol Actions

15-Lipoxygenase inhibitor

PD 146176 blocks neuroprotectin D1 (NPD1) and eicosanoid synthesis by inhibiting the 5-lipoxygenase-1 (15-LOX-1) enzyme.

Features and Benefits

This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573534 PD 146176, >=98% (HPLC), solid white to beige 100 ZGOOPZVQMLHPFM-UHFFFAOYSA-N 1S/C15H11NS/c1-3-7-13-10(5-1)12-9-17-14-8-4-2-6-11(14)15(12)16-13/h1-8,16H,9H2 SIGMA-ALDRICH solid ≥98% (HPLC)
£734.04 (exc VAT) per 25MG
-
+
3573535 PD 146176, >=98% (HPLC), solid white to beige 100 ZGOOPZVQMLHPFM-UHFFFAOYSA-N 1S/C15H11NS/c1-3-7-13-10(5-1)12-9-17-14-8-4-2-6-11(14)15(12)16-13/h1-8,16H,9H2 SIGMA-ALDRICH solid ≥98% (HPLC)
£289.71 (exc VAT) per 5MG
-
+